Pediatrix Medical Group, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $1.30B
  • PE -13
  • Debt $636.17M
  • Cash $229.94M
  • EV $1.71B
  • FCF $195.23M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$99.07M
EBIT-$68.71M
ROE-13%
ROA-3%
FCF$195.23M
Equity$764.94M
Growth Stability-492%
PE-13.12
PEG-7.03
PB1.7
P/FCF6.66
P/S0.65
Price/Cash0.18
Debt/Equity0.83
Debt/FCF3.26
Net Margins-5%
Op. Margins-3%
Earnings CAGR-5%
Sales Growth YoY1%
Sales Growth QoQ-2%
Sales CAGR-8%
FCF CAGR-16%
Equity CAGR-16%
Earnings Stability0.13
Earnings Growth YoY-125%
Earnings Growth QoQ57%
Earnings CAGR 5Y2%
Sales CAGR 5Y-3%
FCF CAGR 5Y-12%
Equity CAGR 5Y-3%
Earnings CAGR 3Y1%
Sales CAGR 3Y1%
FCF CAGR 3Y11%
Equity CAGR 3Y-6%
Market Cap$1.30B
Revenue$2.01B
Assets$2.15B
Total Debt$636.17M
Cash$229.94M
Shares Outstanding83.25M
EV1.71B
Earnings Score5%
Moat Score8%
Safety Score58%
Final Score24%
Working Capital205.5M
Current Ratio1.47
Shares Growth 3y-0%
Equity Growth QoQ4%
Equity Growth YoY-10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment, which is physician services. Mednax generates roughly half of its revenue from the women's and children's services provided, and also roughly half of the company's total revenue is earned in the United States.

SEC Filings

Direct access to Pediatrix Medical Group, Inc. (MD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Pediatrix Medical Group, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Pediatrix Medical Group, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%
Stability 13%
loading chart...

Pediatrix Medical Group, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Pediatrix Medical Group, Inc..

= $723M
012345678910TV
fcf$195M$164M$138M$116M$98M$82M$69M$58M$49M$41M$34M$345M
DCF$149M$114M$87M$67M$51M$39M$30M$23M$17M$13M$133M
Value$723M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins12%10%9%7%-43%-46%7%3%-3%-5%-5%
ROA-11%8%8%-27%3%7%7%0%-3%-3%
ROE-12%10%9%-100%-107%15%7%-7%-13%-13%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-4.294.038.255.569.9512.34.325.73.263.26
Debt over Equity0.530.630.610.641.172.341.120.740.760.830.83
Growth Stability---82%-492%-----217%-492%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-15%9%5%-4%-51%10%3%1%1%-3%
Earnings YoY growth--3%-1%-16%-658%-47%-116%-49%-191%64%2%
Equity YoY growth-13%11%1%-51%-50%20%-1%-5%-10%-3%
FCF YoY growth-18%14%-48%31%-44%-54%87%-26%73%-12%